Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_709b4a26ef028713f9b302509eb824d7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001119 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
filingDate |
2002-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fbfa5c7f4ecec46fa33bee0dcc3a83f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f165404e503b601042f94498072716f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50651b29f9e85db4ab66ef3942f2d325 |
publicationDate |
2003-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-03092717-A1 |
titleOfInvention |
Cancer immunotherapy |
abstract |
A method for stimulating an immune response against IL-12Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating an immune response agaist IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11712465-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10137182-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006110603-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8097256-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3480212-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9433667-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9095538-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2193805-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110022894-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11096996-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2193805-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10226519-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021230792-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9068020-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9023338-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9382308-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019086676-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018065625-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11472862-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8871211-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11478537-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11478538-B2 |
priorityDate |
2002-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |